elbasvir; grazoprevir · Msd Sub Merck · NDA 208261
Zepatier
Earliest generic entry, as listed
4 May 2031
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 8871759.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8871759 | drug substance, drug product, use U-1813 · sets the listed date | 4 May 2031 |
| US 7973040 | drug substance, drug product, use U-1813 | 24 Jul 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 208261 · 001 · RLD · discontinued | tablet, oral | 50MG;100MG | 4 May 2031 |